Lung Cancer Therapeutics Market Research and Analysis 2025

Abnormal cell growth can lead to cancer. Cells that grow uncontrollably invade nearby tissues and further spread to other parts of the body through the lymphatic system. Lung cancer, also known as lung carcinoma, is characterized by uncontrolled cell growth in lungs. There are three major types of lung cancer: non-small cell lung cancer, small cell lung cancer, and lung carcinoid tumor. Non-small cell lung cancer is the common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Common symptoms of lung cancer include coughing, chest pains, weight loss, and shortness of breath. Lung cancer can be treated through various types of therapies such as chemotherapy, radiation therapy, vaccines, and immunotherapies.

Get Sample Copy of this Report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5153

According to Centers for Disease Control and Prevention (CDC), lung cancer is the primary cause of cancer death and the second most common cancer. The global lung cancer therapeutics market is expected to expand at a rapid pace during the forecast period due to the increase in incidence of lung cancer. Cigarette smoking, pipes, cigar smoking, and constant exposure to asbestos are the key factors that can cause lung cancer. Prominent factors driving the global lung cancer therapeutics market include increase in geriatric population and rise in prevalence of unhealthy lifestyles. Availability of generic drugs, poor cancer diagnostic facilities in many countries, high cost and the adverse effect of radiation and chemotherapies are the factors likely to restrain the global lung cancer therapeutics market during the forecast period.

The global lung cancer therapeutics market can be segmented based on chemotherapy, targeted therapy, radiotherapy, and geography. Based on chemotherapy, the global lung cancer therapeutics market can be categorized into Gemzar, Alimta, Paraplatin, Taxotere, Navelbine, and others. Chemotherapy is usually based on the combination of drugs. In terms of targeted therapy, the global lung cancer therapeutics market can be divided into Avastin, Tarceva, Iressa, Gilotrif, and others. Based on radiotherapy, the global lung cancer therapeutics market can be segregated into external beam radiotherapy, internal radiotherapy, and systemic radiotherapy.

Geographically, the lung cancer therapeutics market can be segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is expected to dominate the global lung cancer therapeutics market in the near future, due to extensive technological advancements in the region.

Europe is anticipated to be the second largest market for lung cancer therapeutics owing to the large government funding in the field of research and development of novel drugs and technological advancements in the fields of cancer. The global lung cancer therapeutics market in Asia Pacific is estimated to expand at a rapid pace the during the forecast period primarily owing to the development in healthcare facilities, rise in awareness about health, and increase in government funding. In terms of revenue, the lung cancer therapeutics market in China and India is likely to expand significantly owing to the increase in population, development of economies, rise in prevalence of unhealthy lifestyle, and surge in air pollution.

View Report @ http://www.transparencymarketresearch.com/lung-cancer-therapeutics-markets.html

Key players operating in the global lung cancer therapeutics market are adopting various strategies such as acquisition and mergers, development of new and efficient drugs, geographical expansion, and strong research and development activities in order to maintain their position in the market. Prominent players operating in the global lung cancer therapeutics market include F. Hoffmann-La Roche Ltd., AstraZeneca plc, GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., Pfizer, Inc., Agennix AG, and Eli Lilly and Company.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

This release was published on openPR.